Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-15 · accession 0001842190-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-17 | 2025-12-16 | TARS | Lin Elizabeth Yeu | Chief Medical Off | S - Sale+OE | $79.50 | -2,078 | 21.9K | -9% | -$165.2K |
| D | 2025-12-17 | 2025-12-15 | TARS | Lin Elizabeth Yeu | Chief Medical Off | M - OptEx | — | +6,819 | 24.0K | +40% | — |
| D | 2025-12-17 | 2025-12-15 | TARS | Lin Elizabeth Yeu | Chief Medical Off | M - OptEx | $0.00 | -6,819 | 20.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-16 | S | D | 2,078 | $79.50 | 21,941 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-15 | M | A | 6,819 | — | 24,019 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. (F2) Since the date of the Reporting Person's last report, 9,506 shares previously owned by the Reporting Person's Spouse's Roth IRA were transferred to the Reporting Person's self-directed IRA and are now directly owned. |
| 3 | Derivative | Restricted Stock Units | 2025-12-15 | M | D | 6,819 | $0.00 | 20,459 | D | — · — to — | 6,819 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Company's common stock. (F5) RSUs granted on November 4, 2024 in connection with the Reporting Person's appointment as Chief Medical Officer. 25% of the RSUs will vest on December 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. |